Non-HDL cholesterol is calculated as total cholesterol minus HDL-C. It captures every atherogenic particle your lipid panel measures (LDL, VLDL, IDL, and Lp(a) cholesterol) in a single number.
Non-HDL is a stronger cardiovascular risk predictor than LDL-C alone, especially when triglycerides are elevated or LDL-C reporting is unreliable. It's also the guideline-preferred treatment target when ApoB testing isn't available. Longevity targets are tighter than standard clinical thresholds, with under 130 mg/dL optimal and under 100 mg/dL for aggressive primary prevention.
Optimal Non-HDL Cholesterol: 0-130 mg/dL.
Typically re-tested every 10 weeks.
Non-HDL cholesterol is the cholesterol carried inside every lipoprotein particle in your blood apart from HDL, calculated by subtracting HDL cholesterol from total cholesterol.
That subtraction does something useful. Cholesterol does not float freely in plasma, it travels inside protein-wrapped particles. One family of those particles carries a structural protein called apolipoprotein B, one molecule per particle. That family includes LDL, VLDL, intermediate-density lipoproteins, chylomicron remnants and lipoprotein(a). These are the particles able to cross the lining of the artery wall and become trapped there, where the cholesterol they carry accumulates inside developing plaque[1]. HDL particles behave differently and are deliberately left out of the calculation.
So what remains after you remove the HDL fraction is the cholesterol riding inside apoB-containing particles. Published reviews describe non-HDL cholesterol as a practical, calculation-only estimate of the total atherogenic lipoprotein burden[1]. Nothing extra is drawn and nothing extra is billed. If a lipid panel reports total cholesterol and HDL cholesterol, your non-HDL value is already contained in that result whether the lab prints the line or not.
Two features make it worth reading. It needs no assumptions about triglyceride levels, unlike the long-used Friedewald equation for estimating LDL cholesterol, which becomes less reliable when triglycerides are elevated[1]. And it counts remnant cholesterol, the cholesterol carried by partially metabolised triglyceride-rich particles, which conventional LDL cholesterol reporting leaves out[2].
Related: Non-HDL Cholesterol Calculator (How to Read Your Result)
It matters because it captures the entire pool of cholesterol most closely tied to atherosclerosis rather than one slice of it.
Atherosclerosis is widely understood as a retention process. ApoB-containing particles enter the artery wall, some are held there, and over years the trapped cholesterol drives the inflammatory changes that build plaque. The more of that cholesterol circulating, the more opportunity for retention. Reviews of non-HDL cholesterol in dyslipidemia report that it tracks closely with apolipoprotein B measurements and performs well as a marker of that burden[1].
The number earns its place most clearly when triglycerides are raised. In insulin resistance, type 2 diabetes and metabolic syndrome, LDL cholesterol can look reassuring while triglyceride-rich remnant particles are elevated and unaccounted for[2]. Non-HDL cholesterol folds those remnants back into the picture, which is why lipid testing reviews describe it as a useful secondary target alongside LDL cholesterol[3].
One limitation is worth knowing. Lipoprotein(a) is an apoB particle, so its cholesterol is included in the non-HDL total, but it contributes variably and is recognised as an independent, largely genetically determined risk factor that is measured on its own[4]. A reassuring non-HDL result does not tell you anything about your lipoprotein(a).
Non-HDL cholesterol is a risk marker, not a diagnosis. It describes a probability across populations over decades, not a prediction about one person in one year.
Most laboratories report non-HDL cholesterol up to 160 mg/dL as within the standard reference range, while FitScript's optimal range is 0 to 130 mg/dL.
| Measure | Range | What it represents |
|---|---|---|
| Typical lab reference range | 0 to 160 mg/dL (roughly up to 4.1 mmol/L) | The band most labs report as within range for adults |
| FitScript optimal range | 0 to 130 mg/dL (roughly up to 3.4 mmol/L) | FitScript's optimization target, tighter than the standard range |
Non-HDL cholesterol rises with age. In a population study of 1,011 adults it climbed from the twenties to the fifties in men and kept rising into the sixties in women.[13]
| Sex | Age | 5th to 95th percentile (mg/dL) |
|---|---|---|
| Men | 18 to 29 | 73 to 163 |
| Men | 30 to 39 | 91 to 202 |
| Men | 40 to 49 | 108 to 226 |
| Men | 50 to 59 | 102 to 236 |
| Women | 18 to 29 | 76 to 171 |
| Women | 30 to 39 | 83 to 176 |
| Women | 40 to 49 | 88 to 205 |
| Women | 60 to 69 | 111 to 226 |
These show where most adults fall, not a healthy target; heart-risk targets are lower than the top of these ranges. Your own lab's printed range is the one to read your result against.
Reference ranges vary by laboratory, assay, age and sex, so read your own report's printed range first. FitScript's optimal range is an optimization target, not a diagnostic cut-off, and sitting above it does not mean a condition is present.
No age-specific or sex-specific optimal ranges are published here, because none are defined for this marker. Context matters more than either column anyway. Clinicians commonly work toward lower personal targets for people who already have established cardiovascular disease, diabetes or a strong family history, and lipid testing reviews discuss non-HDL goals being set relative to individual risk rather than a single universal number[3]. A single value is also a snapshot. Lipids vary between draws, so a trend across repeat testing says more than one result.
A result above the standard range means more cholesterol is circulating inside atherogenic particles than expected, which is associated with higher long-term cardiovascular risk. It is an observation, not a diagnosis.
What people notice. Usually nothing. Elevated non-HDL cholesterol produces no symptoms in the vast majority of people, which is the entire reason it is screened rather than waited for. In marked or inherited lipid disorders, visible deposits can appear, such as yellowish plaques around the eyelids, thickening of the Achilles or knuckle tendons, or a pale ring at the edge of the cornea in younger adults. When very high triglycerides drive the result, abdominal pain can reflect pancreatic involvement, and severe hypertriglyceridaemia is studied specifically for its link to pancreatitis risk[5]. Pain of that kind is worth discussing with a clinician promptly.
What commonly sits behind it. Dietary pattern, particularly saturated fat intake and low fibre intake. Excess body fat and insulin resistance, which shift the particle mix toward triglyceride-rich remnants[2]. Underactive thyroid function. Kidney disease with protein loss, and some liver and biliary conditions. Regular heavy alcohol intake. Pregnancy, which raises lipids physiologically. Certain prescribed medications. And genetics, including familial hypercholesterolaemia and familial combined hyperlipidemia, where values run high from early life despite reasonable habits[1].
What it may mean over time. Sustained elevation is associated with faster plaque accumulation and a higher lifetime likelihood of cardiovascular events. The exposure is cumulative, which is why duration matters as much as peak value.
What is worth doing. Bring the result to a clinician alongside the rest of the lipid panel, blood pressure, fasting glucose or HbA1c, and family history, and ask whether a repeat draw and a lipoprotein(a) measurement would add useful information. A suboptimal number interpreted on its own tends to be either over-read or dismissed.
A low non-HDL cholesterol result is usually a favourable finding, and for most people it reflects either habits, genetics or effective lipid-lowering treatment.
What people notice. Typically nothing at all. There is no recognised symptom set attached to a low non-HDL value itself. Where symptoms exist, they generally belong to whatever is driving the number down.
What can sit behind it. Favourable genetics and a dietary pattern low in saturated fat are common explanations. So is treatment, since lipid-lowering therapy is designed to produce exactly this change, and large reviews of statin therapy report that benefits in appropriately selected patients outweigh the risks[6]. A genuinely low result with no obvious explanation, especially if it has fallen without any deliberate change, can accompany overactive thyroid function, malabsorption or coeliac disease, advanced liver disease, chronic inflammation, significant undernutrition, or other serious illness. That pattern is worth raising with a clinician rather than filing away as good news.
What it may mean over time. Lower lifetime exposure to apoB-carried cholesterol is associated with lower cardiovascular risk, and the concern once raised about very low achieved cholesterol levels on therapy has not been borne out in the safety literature reviewed to date[6]. The useful question with an unexplained low value is not whether the number is too good, but what changed.
Several things move this number, some of them nothing to do with your arteries.
Testing conditions. Non-HDL cholesterol is calculated from two directly measured values, so it is relatively robust compared with estimated LDL cholesterol, and reviews of lipid profile testing support non-fasting sampling for most routine assessment[3]. A very fatty meal shortly before a draw can still raise triglyceride-rich particles. Acute illness, infection, recent surgery or a recent cardiac event can temporarily lower lipid values for weeks, so a result taken during that window may understate your usual level. Prolonged tourniquet time, standing versus lying posture and dehydration cause smaller shifts. Biological variation alone means two honest draws a fortnight apart will rarely match exactly.
Medications and treatments. Several drug classes are studied for their effect on atherogenic lipoproteins. Statins remain the most extensively reviewed[6]. Oral PCSK9 inhibition has been examined in placebo-controlled trial settings[7]. Weight-loss pharmacotherapy including oral GLP-1 receptor agonists has been trialled for effects on body weight and cardiometabolic measures[8]. Newer agents aimed at triglyceride-rich lipoproteins include RNA interference therapies targeting ANGPTL3[9] and APOC3[10], and antisense approaches studied in people with hypertriglyceridemia at high cardiovascular risk[11] and in severe hypertriglyceridemia[5]. Several of these remain investigational. Any of them is a prescription decision, and a licensed provider evaluates whether a given therapy is appropriate for an individual after reviewing their full clinical picture. No dosing, schedule or administration guidance belongs on a page like this one. Other medications can raise lipids as a side effect, which is one reason your full medication list belongs in the conversation.
Habits. Reducing saturated fat intake, increasing viscous fibre, losing excess body fat, regular aerobic activity, moderating alcohol and stopping smoking are each associated with more favourable lipid profiles, though the size of the effect varies widely between individuals. Research also suggests a dose-response association between omega-3 fatty acid intake and improvements in some lipid measures[12]. Habits move triglyceride-rich particles more readily than they move LDL in many people, which is part of why non-HDL cholesterol is a sensible number to track through a lifestyle change.
Non-HDL cholesterol comes out of the standard lipid panel, which is part of FitScript's Heart Health labs, so no separate test is needed once total cholesterol and HDL cholesterol are measured. Membership covers 150+ biomarkers tested per year, which means the value is captured repeatedly rather than once.
Atlas, FitScript's AI health advisor, reads that result in context, alongside your apolipoprotein B, triglycerides, HDL cholesterol, glucose markers and body composition, and writes it up as part of your FitScript so you can see the pattern instead of a lone figure. Repeat draws are the point. A single non-HDL value tells you where you are standing; four values across a year tell you which direction you are walking.
Where a prescription option is being considered, a licensed provider reviews the member and decides whether any treatment is appropriate. This page is educational and is not medical advice. Discuss your own results and any treatment decision with a clinician or licensed provider who knows your history.
Non-HDL cholesterol is most informative as part of a set.
LDL cholesterol remains the most widely used lipid target and is the largest single contributor to the non-HDL figure, though it misses remnant cholesterol. HDL cholesterol is the value subtracted out, and its own level carries separate information. Apolipoprotein B counts the atherogenic particles directly rather than estimating the cholesterol they carry, and reviews report close agreement between apoB and non-HDL cholesterol in most people[1]. Triglycerides identify whether a raised non-HDL result is being driven by remnant-rich particles[2]. Total cholesterol is the starting figure for the calculation and is best read as a component rather than a conclusion. The cholesterol to HDL ratio offers a quick index of the balance between the two fractions. Lipoprotein(a), measured separately and usually only once or twice in a lifetime, captures an inherited risk that the rest of the panel cannot see[4].
Outside the lipid panel, markers of glucose control and inflammation are often read at the same time, because insulin resistance and lipid patterns tend to move together.
If your last lipid panel printed total cholesterol and HDL cholesterol, you already have this number. Under 160 mg/dL is what most labs report as within range, under 130 mg/dL is FitScript's optimal range, and the direction of travel across repeat tests usually matters more than any one draw. Bring the result, the rest of the panel and your family history to a clinician, and let the interpretation happen with all of it on the table.
For the related markers, see the dedicated pages for LDL Cholesterol, HDL Cholesterol, Apolipoprotein B, Triglycerides, Cholesterol - Total and the Cholesterol / HDL Ratio, all of which are measured together in the Heart Health panel.
Calculators that use Non-HDL Cholesterol:
Subtract your HDL cholesterol from your total cholesterol. If total cholesterol is 200 mg/dL and HDL cholesterol is 55 mg/dL, non-HDL cholesterol is 145 mg/dL. No extra blood, no extra assay and no fasting requirement, the value is already contained in any standard lipid panel that reports both figures.
Most laboratories report values up to 160 mg/dL as within the standard reference range for adults, which is roughly 4.1 mmol/L. FitScript's optimal range is 0 to 130 mg/dL, about 3.4 mmol/L. Ranges vary by lab, assay, age and sex, so check the printed range on your own report first.
It adds information rather than replacing LDL cholesterol. Non-HDL includes remnant cholesterol from triglyceride-rich particles that conventional LDL reporting leaves out, and it stays reliable when triglycerides are high, which is when calculated LDL becomes less accurate. Reviews describe it as a useful secondary target alongside LDL cholesterol.
Usually not. Reviews of lipid profile testing support non-fasting sampling for most routine assessment, and because non-HDL is calculated from two directly measured values it is less sensitive to fasting status than estimated LDL cholesterol. Follow whatever instruction your ordering clinician or lab gives for your particular draw.
It means more cholesterol is circulating in plaque-forming particles than expected, which is associated with higher long-term cardiovascular risk. It is not a diagnosis and it does not identify a cause on its own. Common contributors include diet, excess body fat, insulin resistance, thyroid or kidney issues, alcohol, some medications and inherited lipid disorders.
For most people a low value is favourable and often reflects habits, genetics or effective lipid-lowering treatment. An unexplained drop is the situation worth attention, since it can accompany overactive thyroid function, malabsorption, liver disease, chronic inflammation or undernutrition. Raise an unexplained fall with a clinician rather than assuming it is simply good news.
Lipid values shift over weeks to months with sustained dietary, body composition and activity changes, and they also vary naturally between draws. Acute illness, infection or recent surgery can temporarily lower lipids for several weeks. Because of that variability, a trend across repeat testing is more informative than any single result.
They answer different questions. Apolipoprotein B counts atherogenic particles directly rather than estimating the cholesterol inside them, and reviews report close agreement with non-HDL cholesterol in most people. Lipoprotein(a) is largely genetically determined, is recognised as an independent risk factor, and is not revealed by a reassuring non-HDL value.